-+ 0.00%
-+ 0.00%
-+ 0.00%

ACUMEN PHARMACEUTICALS HIGHLIGHTS ENHANCED BRAIN DELIVERY™ TECHNOLOGY FOR OLIGOMER-SELECTIVE ANTIBODIES AND RECRUITMENT STRATEGIES FOR PHASE 2 ALTITUDE-AD CLINICAL TRIAL AT 18TH ANNUAL CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE

Reuters·12/02/2025 13:00:03

Please log in to view news